NCT01453023View on ClinicalTrials.gov

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Asthma
Interventions
DRUG

Fluticasone Furoate

100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.

DRUG

Fluticasone Furoate/Vilanterol

100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.

Trial Locations (1)

92647

GSK Investigational Site, Huntington Beach

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01453023 - Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study | Biotech Hunter | Biotech Hunter